Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9UIQ6
UPID:
LCAP_HUMAN
Alternative names:
Insulin-regulated membrane aminopeptidase; Insulin-responsive aminopeptidase; Oxytocinase; Placental leucine aminopeptidase
Alternative UPACC:
Q9UIQ6; O00769; Q15145; Q59H76; Q9TNQ2; Q9TNQ3; Q9UIQ7
Background:
Leucyl-cystinyl aminopeptidase, known by alternative names such as Insulin-regulated membrane aminopeptidase, Insulin-responsive aminopeptidase, Oxytocinase, and Placental leucine aminopeptidase, plays a pivotal role in various physiological processes. It is instrumental in the release of N-terminal amino acids, cleaving before cysteine, leucine, and other amino acids. This enzyme is crucial for degrading peptide hormones like oxytocin, vasopressin, and angiotensin III, thereby maintaining homeostasis during pregnancy. Additionally, it contributes to the inactivation of neuronal peptides in the brain and binds angiotensin IV, potentially acting as the angiotensin IV receptor in the brain.
Therapeutic significance:
Understanding the role of Leucyl-cystinyl aminopeptidase could open doors to potential therapeutic strategies.